NDAORALSOLUTION
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
SODIUM IODIDE I 131 (sodium iodide i-131) by PharmaIN is sodium-iodide symporter (nis) protein, in thyroid follicular cells. Approved for hyperthyroidism, selected cases of carcinoma of the thyroid. First approved in 1976.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Iodide I-131 is an oral radioactive iodine solution approved since 1976 for treating hyperthyroidism and selected thyroid carcinomas. The drug works by concentrating in thyroid follicular cells via the sodium-iodide symporter, where beta emission from I-131 destroys thyroid tissue. It represents a foundational nuclear medicine approach to thyroid disease management.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure; brand teams are likely focused on defending market position and managing transition planning.
Mechanism of Action
sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I) which in turn iodinates tyrosine residues of thyroglobulin (tri…
Indications (2)
Worked on SODIUM IODIDE I 131 at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.